The discovery of the potent aurora inhibitor MK-0457 (VX-680)

被引：90

作者：

Bebbington, David ^{[1
]}

Binch, Hayley ^{[1
]}

Charrier, Jean-Damien ^{[1
]}

Everitt, Simon ^{[1
]}

Fraysse, Damien ^{[1
]}

Golec, Julian ^{[1
]}

Kay, David ^{[1
]}

Knegtel, Ronald ^{[1
]}

Mak, Chau ^{[1
]}

Mazzei, Francesca ^{[1
]}

Miller, Andrew ^{[1
]}

Mortimore, Michael ^{[1
]}

O'Donnell, Michael ^{[1
]}

Patel, Sanjay ^{[1
]}

Pierard, Francoise ^{[1
]}

Pinder, Joanne ^{[1
]}

Pollard, John ^{[1
]}

Ramaya, Sharn ^{[1
]}

Robinson, Daniel ^{[1
]}

Rutherford, Alistair ^{[1
]}

Studley, John ^{[1
]}

Westcott, James ^{[1
]}

机构：

[1] Vertex Pharmaceut Europe Ltd, Abingdon OX14 4RY, Oxon, England

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2009年 / 19卷 / 13期

关键词：

Aurora; Kinase inhibitor; SAR; KINASE INHIBITORS; ANTICANCER AGENTS; CANCER; FAMILY; ABL; MUTANT; CELLS;

D O I：

10.1016/j.bmcl.2009.04.136

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

The identification of a novel series of Aurora kinase inhibitors and exploitation of their SAR is described. Replacement of the initial quinazoline core with a pyrimidine scaffold and modi. cation of substituents led to a series of very potent inhibitors of cellular proliferation. MK-0457 (VX-680) has been assessed in Phase II clinical trials in patients with treatment-refractory chronic myelogenous leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL) containing the T315I mutation. (C) 2009 Elsevier Ltd. All rights reserved.

引用

页码：3586 / 3592

页数：7

共 32 条

[11] Aurora kinases as anticancer drug targets [J].

Gautschi, Oliver ;

Heighway, Jim ;

Mack, Philip C. ;

Purnell, Phillip R. ;

Lara, Primo N., Jr. ;

Gandara, David R. .

CLINICAL CANCER RESEARCH, 2008, 14 (06) :1639-1648

[12] Aurora kinase inhibitors: A new class of targeted drugs in cancer [J].

Gautschi, Oliver ;

Mack, Philip C. ;

Davies, Angela M. ;

Lara, Primo N., Jr. ;

Gandara, David R. .

CLINICAL LUNG CANCER, 2006, 8 (02) :93-98

[13]

Giet R, 1999, J CELL SCI, V112, P3591

[14]

Giles F CJ, 2006, BLOOD, V108

[15] MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation [J].

Giles, Francis J. ;

Cortes, Jorge ;

Jones, Dan ;

Bergstrom, Donald ;

Kantarjian, Hagop ;

Freedman, Steven J. .

BLOOD, 2007, 109 (02) :500-502

[16] Molecular basis of drug resistance in Aurora kinases [J].

Girdler, Fiona ;

Sessa, Fabio ;

Patercoli, Simona ;

Villa, Fabrizio ;

Musacchio, Andrea ;

Taylor, Stephen .

CHEMISTRY & BIOLOGY, 2008, 15 (06) :552-562

[17] The Aurora kinase inhibitor VX-680 induces endoreduplication and apoptosis preferentially in cells with compromised p53-dependent postmitotic checkpoint function [J].

Gizatullin, Farid ;

Yao, Yao ;

Kung, Victor ;

Harding, Matthew W. ;

Loda, Massimo ;

Shapiro, Geoffrey I. .

CANCER RESEARCH, 2006, 66 (15) :7668-7677

[18] MUTATIONS IN AURORA PREVENT CENTROSOME SEPARATION LEADING TO THE FORMATION OF MONOPOLAR SPINDLES [J].

GLOVER, DM ;

LEIBOWITZ, MH ;

MCLEAN, DA ;

PARRY, H .

CELL, 1995, 81 (01) :95-105

[19] VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo [J].

Harrington, EA ;

Bebbington, D ;

Moore, J ;

Rasmussen, RK ;

Ajose-Adeogun, AO ;

Nakayama, T ;

Graham, JA ;

Demur, C ;

Hercend, T ;

Diu-Hercend, A ;

Su, M ;

Golec, JMC ;

Miller, KM .

NATURE MEDICINE, 2004, 10 (03) :262-267

[20] Fragment-Based Discovery of the Pyrazol-4-yl Urea (AT9283), a Multitargeted Kinase Inhibitor with Potent Aurora Kinase Activity [J].

Howard, Steven ;

Berdini, Valerio ;

Boulstridge, John A. ;

Carr, Maria G. ;

Cross, David M. ;

Curry, Jayne ;

Devine, Lindsay A. ;

Early, Theresa R. ;

Fazal, Lynsey ;

Gill, Adrian L. ;

Heathcote, Michelle ;

Maman, Sarita ;

Matthews, Julia E. ;

McMenamin, Rachel L. ;

Navarro, Eva F. ;

O'Brien, Michael A. ;

O'Reilly, Marc ;

Rees, David C. ;

Reule, Matthias ;

Tisi, Dominic ;

Williams, Glyn ;

Vinkovic, Mladen ;

Wyatt, Paul G. .

JOURNAL OF MEDICINAL CHEMISTRY, 2009, 52 (02) :379-388

← 1 2 3 4 →